BRCA1 and BRCA2 Testing for Breast Cancer: Who Should Test — and What to Do After a Positive Result in India

A BRCA mutation raises lifetime breast cancer risk to 55–72%. It also changes surgery decisions, opens PARP inhibitor eligibility, and has implications for your family. This guide covers who should test, what a positive result means for treatment, and how India's top cancer centres manage BRCA-positive breast cancer — including bilateral mastectomy and olaparib — at 85–90% lower cost than the US.

By Gaf Healthcare Editorial Team

2026-05-09

<!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>BRCA1 and BRCA2 Testing for Breast Cancer: Who Should Test — and What to Do After a Positive Result in India</title> <meta name="description" content="BRCA1 or BRCA2 mutation? Learn who should be tested, what a positive result means for your treatment, and how India's top centres manage BRCA-positive breast cancer at 85% lower cost."> <link rel="preconnect" href="https://fonts.googleapis.com"> <link href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,600;1,400&family=Source+Sans+3:wght@400;500;600&display=swap" rel="stylesheet"> <style> , ::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }

:root { --cream: #F5F2EB; --cream-dark: #EDE9DF; --green-dark: #1B5E3B; --green-mid: #2D7A52; --green-light: #EAF4EE; --green-border: #C2DFCC; --red-accent: #B84040; --red-bg: #FDF2F2; --amber: #B07A15; --amber-bg: #FDF7EC; --amber-border: #E8D5A0; --purple: #6B50A8; --purple-bg: #F0EDF8; --purple-border: #CFC8E8; --text-primary: #1A1A18; --text-body: #2E2E2A; --text-muted: #6B6860; --text-green: #1B5E3B; --border-soft: #DDD9CF; }

body { font-family: 'Source Sans 3', sans-serif; background-color: var(--cream); color: var(--text-body); font-size: 18px; line-height: 1.75; -webkit-font-smoothing: antialiased; }

.page-wrap { max-width: 740px; margin: 0 auto; padding: 48px 24px 80px; }

.meta-tag { display: inline-block; font-size: 11px; font-weight: 600; letter-spacing: 0.12em; text-transform: uppercase; color: var(--text-green); background: var(--green-light); border: 1px solid var(--green-border); border-radius: 4px; padding: 3px 10px; margin-bottom: 18px; }

h1 { font-family: 'Lora', Georgia, serif; font-size: clamp(26px, 4vw, 38px); font-weight: 600; line-height: 1.25; color: var(--text-primary); margin-bottom: 18px; letter-spacing: -0.01em; }

.deck { font-size: 19px; line-height: 1.6; color: var(--text-muted); margin-bottom: 28px; border-bottom: 1px solid var(--border-soft); padding-bottom: 28px; }

/ ILLUSTRATION / .illustration-wrap { margin: 8px 0 36px; border-radius: 10px; overflow: hidden; border: 1px solid var(--border-soft); background: var(--cream-dark); } .illustration-wrap svg { display: block; width: 100%; } .img-caption { font-size: 13px; color: var(--text-muted); padding: 10px 16px 12px; border-top: 1px solid var(--border-soft); font-style: italic; line-height: 1.6; }

/ TOC / .toc-box { background: var(--cream-dark); border: 1px solid var(--border-soft); border-radius: 10px; padding: 20px 24px 24px; margin: 0 0 40px; } .toc-label { display: flex; align-items: center; gap: 8px; font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-muted); margin-bottom: 14px; } .toc-label::before { content: ""; display: inline-block; width: 14px; height: 14px; background: var(--border-soft); border-radius: 2px; } .toc-box ol { list-style: none; padding: 0; display: flex; flex-direction: column; gap: 8px; } .toc-box ol li a { color: var(--text-green); text-decoration: none; font-size: 16px; font-weight: 500; border-bottom: 1px solid transparent; transition: border-color 0.15s; } .toc-box ol li a:hover { border-color: var(--green-mid); }

/ PROSE / .prose h2 { font-family: 'Lora', Georgia, serif; font-size: clamp(20px, 3vw, 26px); font-weight: 600; color: var(--text-primary); margin: 44px 0 6px; padding-bottom: 12px; border-bottom: 1px solid var(--border-soft); letter-spacing: -0.01em; }

.prose p { font-family: 'Lora', Georgia, serif; font-size: 18px; line-height: 1.82; color: var(--text-body); margin-bottom: 16px; max-width: 68ch; } .prose p strong { font-weight: 600; color: var(--text-primary); } .prose p.impact { font-size: 19px; font-style: italic; color: var(--text-muted); border-left: 3px solid var(--green-mid); padding-left: 18px; margin: 24px 0; }

/ QUICK ANSWER / .quick-box { background: var(--green-light); border: 1.5px solid var(--green-border); border-radius: 10px; padding: 20px 24px 22px; margin: 20px 0 24px; } .quick-box .qa-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--amber); display: flex; align-items: center; gap: 6px; margin-bottom: 10px; } .quick-box .qa-label::before { content: "⚡"; font-size: 13px; } .quick-box .qa-question { font-family: 'Source Sans 3', sans-serif; font-weight: 600; font-size: 17px; color: var(--text-primary); margin-bottom: 10px; } .quick-box .qa-answer { font-family: 'Source Sans 3', sans-serif; font-size: 16px; line-height: 1.7; color: var(--text-body); } .quick-box .qa-answer strong { color: var(--text-primary); }

/ RISK STAT CARDS / .risk-grid { display: grid; grid-template-columns: 1fr 1fr 1fr; gap: 12px; margin: 20px 0 28px; } .risk-card { border-radius: 10px; padding: 16px 14px 18px; text-align: center; border: 1px solid var(--border-soft); } .risk-card.general { background: var(--cream-dark); } .risk-card.brca1 { background: var(--red-bg); border-color: #E8BABA; } .risk-card.brca2 { background: var(--amber-bg); border-color: var(--amber-border); } .risk-card .risk-label { font-family: 'Source Sans 3', sans-serif; font-size: 10px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; margin-bottom: 8px; } .risk-card.general .risk-label { color: var(--text-muted); } .risk-card.brca1 .risk-label { color: var(--red-accent); } .risk-card.brca2 .risk-label { color: var(--amber); } .risk-card .risk-val { font-family: 'Source Sans 3', sans-serif; font-size: 28px; font-weight: 600; line-height: 1.1; margin-bottom: 4px; } .risk-card.general .risk-val { color: var(--text-muted); } .risk-card.brca1 .risk-val { color: var(--red-accent); } .risk-card.brca2 .risk-val { color: var(--amber); } .risk-card .risk-sub { font-family: 'Source Sans 3', sans-serif; font-size: 11px; color: var(--text-muted); line-height: 1.4; }

/ CHECKLIST / .checklist { list-style: none; padding: 0; margin: 12px 0; display: flex; flex-direction: column; gap: 8px; } .checklist li { display: flex; align-items: flex-start; gap: 10px; font-family: 'Source Sans 3', sans-serif; font-size: 15px; color: var(--text-body); line-height: 1.6; } .check-icon { flex-shrink: 0; width: 20px; height: 20px; border-radius: 50%; background: var(--green-dark); display: flex; align-items: center; justify-content: center; margin-top: 2px; } .check-icon::after { content: "✓"; color: #fff; font-size: 11px; font-weight: 700; }

/ COST TABLE / .cost-table { width: 100%; border-collapse: collapse; border: 1px solid var(--border-soft); border-radius: 8px; overflow: hidden; margin: 18px 0 8px; font-size: 14px; } .cost-table thead th { background: var(--cream-dark); padding: 11px 14px; text-align: left; font-size: 10px; font-weight: 600; letter-spacing: 0.07em; text-transform: uppercase; color: var(--text-muted); border-bottom: 1px solid var(--border-soft); } .cost-table thead th.india-head { background: var(--green-light); color: var(--green-dark); } .cost-table tbody td { padding: 11px 14px; border-bottom: 1px solid var(--border-soft); font-family: 'Source Sans 3', sans-serif; color: var(--text-body); line-height: 1.5; vertical-align: top; } .cost-table tbody tr:last-child td { border-bottom: none; } .cost-table tbody td:first-child { font-weight: 600; color: var(--text-primary); width: 35%; } .cost-table .highlight td { background: #FAFAF7; } .cost-table .saving { color: var(--green-mid); font-weight: 600; } .cost-table .saving-pct { display: inline-block; font-size: 11px; font-weight: 600; background: var(--green-light); color: var(--green-dark); border-radius: 4px; padding: 1px 6px; margin-left: 4px; }

/ OPTION CARDS / .option-grid { display: flex; flex-direction: column; gap: 14px; margin: 20px 0 28px; } .option-card { background: #fff; border: 1px solid var(--border-soft); border-radius: 10px; overflow: hidden; } .option-head { display: flex; align-items: center; gap: 12px; padding: 14px 18px 12px; border-bottom: 1px solid var(--border-soft); background: var(--cream-dark); } .option-num { font-family: 'Lora', Georgia, serif; font-size: 24px; font-weight: 600; color: var(--green-border); line-height: 1; flex-shrink: 0; } .option-head h4 { font-family: 'Source Sans 3', sans-serif; font-size: 16px; font-weight: 600; color: var(--text-primary); line-height: 1.3; } .option-body { padding: 14px 18px 16px; } .option-body p { font-family: 'Source Sans 3', sans-serif; font-size: 15px; color: var(--text-body); line-height: 1.7; margin-bottom: 8px; max-width: none; } .option-body p:last-child { margin-bottom: 0; } .option-body p strong { color: var(--text-primary); font-weight: 600; } .option-foot { padding: 10px 18px 12px; border-top: 1px solid var(--border-soft); background: var(--green-light); } .option-foot p { font-family: 'Source Sans 3', sans-serif; font-size: 13px; color: var(--green-dark); font-weight: 600; margin: 0; max-width: none; }

/ STAT STRIP / .stat-strip { display: grid; grid-template-columns: repeat(auto-fit, minmax(120px, 1fr)); border: 1px solid var(--border-soft); border-radius: 8px; overflow: hidden; margin: 18px 0 24px; } .stat-cell { padding: 14px 16px 16px; border-right: 1px solid var(--border-soft); } .stat-cell:last-child { border-right: none; } .stat-cell .stat-label { font-size: 10px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-muted); margin-bottom: 5px; } .stat-cell .stat-val { font-size: 22px; font-weight: 600; color: var(--green-mid); font-family: 'Source Sans 3', sans-serif; line-height: 1.1; }

/ CALLOUTS / .callout-green { border-left: 3px solid var(--green-mid); background: var(--green-light); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-green .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-green); margin-bottom: 8px; } .callout-red { border-left: 3px solid var(--red-accent); background: var(--red-bg); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-red .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--red-accent); margin-bottom: 8px; } .callout-amber { border-left: 3px solid var(--amber); background: var(--amber-bg); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-amber .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--amber); margin-bottom: 8px; } .callout-purple { border-left: 3px solid var(--purple); background: var(--purple-bg); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-purple .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--purple); margin-bottom: 8px; } .callout-green p, .callout-red p, .callout-amber p, .callout-purple p { font-size: 16px; line-height: 1.7; font-family: 'Source Sans 3', sans-serif; color: var(--text-body); margin: 0; max-width: none; }

.sources-line { font-size: 13px; color: var(--text-muted); margin: 4px 0 24px; font-style: italic; }

/ CTAs / .cta-a { background: var(--green-dark); border-radius: 12px; padding: 28px 28px 30px; margin: 32px 0; } .cta-a .cta-h { font-family: 'Source Sans 3', sans-serif; font-size: 18px; font-weight: 600; color: #fff; margin-bottom: 8px; line-height: 1.4; } .cta-a .cta-s { font-family: 'Source Sans 3', sans-serif; font-size: 15px; color: rgba(255,255,255,.78); margin-bottom: 20px; line-height: 1.6; } .btn-white { display: inline-block; background: #fff; color: var(--green-dark); font-family: 'Source Sans 3', sans-serif; font-size: 15px; font-weight: 600; padding: 11px 22px; border-radius: 6px; text-decoration: none; transition: background 0.15s; } .btn-white:hover { background: #e8f4ee; }

.cta-b { border: 1.5px solid var(--green-border); background: #fff; border-radius: 10px; padding: 20px 22px 22px; margin: 24px 0; display: flex; flex-direction: column; gap: 10px; } .cta-b .cta-h { font-family: 'Source Sans 3', sans-serif; font-size: 16px; font-weight: 600; color: var(--text-primary); line-height: 1.4; } .cta-b .cta-s { font-family: 'Source Sans 3', sans-serif; font-size: 14px; color: var(--text-muted); line-height: 1.6; } .btn-green { display: inline-block; background: var(--green-dark); color: #fff; font-family: 'Source Sans 3', sans-serif; font-size: 14px; font-weight: 600; padding: 10px 20px; border-radius: 6px; text-decoration: none; align-self: flex-start; transition: background 0.15s; } .btn-green:hover { background: var(--green-mid); }

.cta-c { display: flex; align-items: flex-start; gap: 14px; background: var(--cream-dark); border: 1px solid var(--border-soft); border-radius: 8px; padding: 16px 20px; margin: 20px 0; text-decoration: none; transition: border-color 0.15s, background 0.15s; } .cta-c:hover { background: var(--green-light); border-color: var(--green-border); } .cta-c .cta-arrow { font-size: 20px; color: var(--green-mid); line-height: 1; flex-shrink: 0; margin-top: 2px; } .cta-c .rl-label { font-size: 15px; color: var(--green-mid); font-weight: 600; margin-bottom: 4px; font-family: 'Source Sans 3', sans-serif; } .cta-c .rl-desc { font-size: 14px; color: var(--text-muted); font-family: 'Source Sans 3', sans-serif; line-height: 1.5; }

@media (max-width: 580px) { .risk-grid { grid-template-columns: 1fr; } .stat-strip { grid-template-columns: 1fr 1fr; } .cost-table { font-size: 13px; } .cost-table thead th, .cost-table tbody td { padding: 9px 10px; } } </style> </head> <body> <div class="page-wrap">

<span class="meta-tag">Breast Cancer · Genetics · India</span>

<h1>BRCA1 and BRCA2 Testing for Breast Cancer: Who Should Test — and What to Do After a Positive Result in India</h1>

<p class="deck">A BRCA mutation does not mean cancer is inevitable. It means the risk is significantly higher — and that the treatment decisions ahead, including surgery, drug choice, and risk reduction, are meaningfully different. India's top cancer centres manage all of this, at costs that are accessible for international patients.</p>

<div class="illustration-wrap"> <svg viewBox="0 0 700 200" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Scientific diagram illustrating BRCA gene mutation and its effect on DNA repair in breast cancer. The left panel shows a normal BRCA1 or BRCA2 gene functioning correctly — depicted as a double helix DNA strand with a repair protein shown correcting a break in the strand, labelled 'DNA repair working normally.' The right panel shows a mutated BRCA gene — the same double helix but with a red X marking a break that is not being repaired, labelled 'Repair protein absent or non-functional.' Below each panel, a cell diagram shows the outcome: the left cell has a stable nucleus with intact DNA, while the right cell shows an unstable nucleus with accumulated DNA damage, labelled 'Increased risk of cancer cell formation.' A text note explains that BRCA1 mutations are associated with higher breast cancer risk (up to 72% lifetime) and triple-negative subtype prevalence, while BRCA2 mutations carry up to 69% lifetime risk with a higher proportion of hormone receptor-positive cancers. Both genes also increase ovarian cancer risk significantly."> <defs> <linearGradient id="bgBRCA" x1="0" y1="0" x2="0" y2="1"> <stop offset="0%" stop-color="#EDE9DF"/> <stop offset="100%" stop-color="#E4DFCF"/> </linearGradient> </defs> <rect width="700" height="200" fill="url(#bgBRCA)"/>

<text x="175" y="20" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="12" font-weight="600" fill="#1B5E3B" letter-spacing="0.06em">NORMAL BRCA GENE</text> <text x="525" y="20" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="12" font-weight="600" fill="#B84040" letter-spacing="0.06em">MUTATED BRCA GENE</text> <line x1="350" y1="12" x2="350" y2="188" stroke="#DDD9CF" stroke-width="1" stroke-dasharray="4 3"/>

<path d="M120 45 Q145 60 120 75 Q95 90 120 105 Q145 120 120 135" fill="none" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/> <path d="M160 45 Q135 60 160 75 Q185 90 160 105 Q135 120 160 135" fill="none" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/>  <line x1="120" y1="52" x2="160" y2="52" stroke="#C2DFCC" stroke-width="1.5"/> <line x1="120" y1="68" x2="160" y2="68" stroke="#C2DFCC" stroke-width="1.5"/> <line x1="120" y1="84" x2="160" y2="84" stroke="#C2DFCC" stroke-width="1.5"/> <line x1="120" y1="100" x2="160" y2="100" stroke="#C2DFCC" stroke-width="1.5"/> <line x1="120" y1="116" x2="160" y2="116" stroke="#C2DFCC" stroke-width="1.5"/> <line x1="120" y1="132" x2="160" y2="132" stroke="#C2DFCC" stroke-width="1.5"/>  <circle cx="200" cy="90" r="18" fill="#EAF4EE" stroke="#2D7A52" stroke-width="1.5"/> <text x="200" y="87" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="9" fill="#1B5E3B" font-weight="600">BRCA</text> <text x="200" y="98" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="9" fill="#1B5E3B">protein</text> <line x1="183" y1="90" x2="163" y2="90" stroke="#2D7A52" stroke-width="1" marker-end="url(#ag)"/> <defs> <marker id="ag" viewBox="0 0 8 8" refX="6" refY="4" markerWidth="4" markerHeight="4" orient="auto"> <path d="M1 1L7 4L1 7" fill="none" stroke="#2D7A52" stroke-width="1.5" stroke-linecap="round"/> </marker> <marker id="ar" viewBox="0 0 8 8" refX="6" refY="4" markerWidth="4" markerHeight="4" orient="auto"> <path d="M1 1L7 4L1 7" fill="none" stroke="#B84040" stroke-width="1.5" stroke-linecap="round"/> </marker> </defs>  <ellipse cx="175" cy="170" rx="40" ry="18" fill="#EAF4EE" stroke="#C2DFCC" stroke-width="1.5"/> <text x="175" y="174" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#1B5E3B" font-weight="600">Stable cell ✓</text>

<path d="M470 45 Q495 60 470 75 Q445 90 470 105 Q495 120 470 135" fill="none" stroke="#B84040" stroke-width="2.5" stroke-linecap="round"/> <path d="M510 45 Q485 60 510 75 Q535 90 510 105 Q485 120 510 135" fill="none" stroke="#B84040" stroke-width="2.5" stroke-linecap="round"/>  <line x1="470" y1="52" x2="510" y2="52" stroke="#E8BABA" stroke-width="1.5"/> <line x1="470" y1="68" x2="510" y2="68" stroke="#E8BABA" stroke-width="1.5"/>  <line x1="470" y1="84" x2="484" y2="84" stroke="#E8BABA" stroke-width="1.5"/> <line x1="496" y1="84" x2="510" y2="84" stroke="#E8BABA" stroke-width="1.5"/> <text x="490" y="87" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="11" fill="#B84040" font-weight="700">✕</text> <line x1="470" y1="100" x2="510" y2="100" stroke="#E8BABA" stroke-width="1.5"/> <line x1="470" y1="116" x2="510" y2="116" stroke="#E8BABA" stroke-width="1.5"/> <line x1="470" y1="132" x2="510" y2="132" stroke="#E8BABA" stroke-width="1.5"/>  <circle cx="550" cy="90" r="18" fill="#FDF2F2" stroke="#E8BABA" stroke-width="1.5" stroke-dasharray="4 3"/> <text x="550" y="87" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="9" fill="#B84040">mutated</text> <text x="550" y="98" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="9" fill="#B84040">protein</text>  <ellipse cx="525" cy="170" rx="44" ry="18" fill="#FDF2F2" stroke="#E8BABA" stroke-width="1.5"/> <text x="525" y="174" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#B84040" font-weight="600">DNA damage accumulates</text> </svg> <p class="img-caption">How BRCA gene mutations affect DNA repair. Normal BRCA1 and BRCA2 proteins help repair double-strand DNA breaks — a routine type of cellular damage. When these genes are mutated, the repair protein is absent or non-functional. DNA damage accumulates over time, increasing the probability that cells acquire the additional mutations needed to become cancerous. BRCA1 mutations are associated with higher breast cancer risk (up to 72% lifetime) and a higher prevalence of triple-negative breast cancer. BRCA2 mutations carry up to 69% lifetime breast cancer risk with more frequent hormone receptor-positive presentations.</p> </div>

<div class="toc-box"> <div class="toc-label">What's in this guide</div> <ol> <li><a href="#what-brca-means">What BRCA1 and BRCA2 mutations actually mean</a></li> <li><a href="#who-should-test">Who should get tested — the clinical criteria</a></li> <li><a href="#brca-testing-india">BRCA testing in India — cost, turnaround, and process</a></li> <li><a href="#positive-result">What a positive result means for your treatment</a></li> <li><a href="#parp-inhibitors">PARP inhibitors — the drug that targets BRCA mutations</a></li> <li><a href="#bilateral-mastectomy">Bilateral risk-reducing mastectomy in India</a></li> <li><a href="#family-implications">What a positive result means for your family</a></li> </ol> </div>

<h2 id="what-brca-means">What BRCA1 and BRCA2 mutations actually mean</h2>

<p>BRCA1 and BRCA2 are tumour suppressor genes. In a healthy cell, they produce proteins that help repair damaged DNA — a routine process that happens millions of times per day in every cell in your body.</p>

<p>When one of these genes carries a harmful mutation, the repair protein it produces does not work correctly. DNA damage accumulates in cells rather than being corrected. Over time, this increases the probability that cells acquire additional mutations — and eventually become cancerous.</p>

<p>BRCA mutations are inherited. If you carry a BRCA1 or BRCA2 mutation, each of your children has a 50% chance of inheriting it. Your siblings have a 50% chance of carrying the same mutation.</p>

<div class="quick-box"> <div class="qa-label">Quick answer</div> <div class="qa-question">Does a BRCA mutation mean I will definitely get breast cancer?</div> <div class="qa-answer">No — but it significantly raises the risk. The <strong>general population lifetime risk</strong> of breast cancer is around 12%. Women with a <strong>BRCA1 mutation</strong> have a lifetime risk of 55–72%. Women with a <strong>BRCA2 mutation</strong> have a lifetime risk of 45–69%. These are probabilities, not certainties. Many BRCA mutation carriers never develop breast cancer — but the risk is high enough that it changes the clinical conversation about surveillance, prevention, and surgery meaningfully.</div> </div>

<div class="risk-grid"> <div class="risk-card general"> <div class="risk-label">General Population</div> <div class="risk-val">12%</div> <div class="risk-sub">Lifetime breast cancer risk</div> </div> <div class="risk-card brca1"> <div class="risk-label">BRCA1 Mutation</div> <div class="risk-val">55–72%</div> <div class="risk-sub">Lifetime breast cancer risk</div> </div> <div class="risk-card brca2"> <div class="risk-label">BRCA2 Mutation</div> <div class="risk-val">45–69%</div> <div class="risk-sub">Lifetime breast cancer risk</div> </div> </div> <p class="sources-line">Sources: NEJM 2017 (Kuchenbaecker et al.) · National Cancer Institute BRCA fact sheet</p>

<p>BRCA mutations also increase ovarian cancer risk significantly. BRCA1 carriers have a 44% lifetime risk of ovarian cancer. BRCA2 carriers have a 17% lifetime risk — compared to the general population risk of approximately 1.2%.</p>

<p>This is why a BRCA result is not just a breast cancer result. It is a full risk profile that affects multiple organs, multiple treatment decisions, and multiple family members.</p>

<h2 id="who-should-test">Who should get tested — the clinical criteria</h2>

<p>BRCA testing is not recommended universally — the pre-test probability needs to be high enough to justify the result. But the criteria are broader than most patients realise, particularly for women from populations with higher BRCA mutation prevalence.</p>

<ul class="checklist"> <li><span class="check-icon"></span><strong>Diagnosed with breast cancer under 50</strong> — early-onset breast cancer is strongly associated with hereditary risk.</li> <li><span class="check-icon"></span><strong>Triple-negative breast cancer at any age</strong> — BRCA1 mutations are found in approximately 10–20% of TNBC patients. Some guidelines recommend testing all TNBC patients regardless of family history.</li> <li><span class="check-icon"></span><strong>Family history of breast cancer</strong> — particularly a first-degree relative (mother, sister, daughter) diagnosed under 50, or two or more relatives on the same side of the family diagnosed at any age.</li> <li><span class="check-icon"></span><strong>Family history of ovarian, fallopian tube, or primary peritoneal cancer</strong> — strongly associated with BRCA1 mutations in particular.</li> <li><span class="check-icon"></span><strong>Male breast cancer in the family</strong> — male breast cancer is rare and strongly associated with BRCA2 mutations.</li> <li><span class="check-icon"></span><strong>Ashkenazi Jewish ancestry</strong> — BRCA1 and BRCA2 mutations are approximately ten times more prevalent in Ashkenazi Jewish populations than in the general population.</li> <li><span class="check-icon"></span><strong>Known BRCA mutation in the family</strong> — if a blood relative has tested positive, targeted testing for that specific mutation is recommended.</li> <li><span class="check-icon"></span><strong>Bilateral breast cancer</strong> — cancer in both breasts raises the probability of a hereditary cause significantly.</li> </ul>

<div class="callout-amber"> <div class="callout-label">BRCA prevalence in West and East African populations</div> <p>Research into BRCA mutation prevalence in sub-Saharan African populations is ongoing and incomplete — but emerging data suggests that BRCA1 mutations, while present, may follow different founder variant patterns than in European populations. This means standard gene panels may miss some mutations in Nigerian, Ghanaian, or Kenyan patients. At GAF Healthcare's partner hospitals, comprehensive BRCA1/2 sequencing — not just targeted variant testing — is available, which reduces the risk of missing population-specific mutations. If you are from West or East Africa and meet testing criteria, ask specifically for full sequencing rather than panel testing alone.</p> </div>

<div class="cta-b"> <p class="cta-h">Not sure whether you meet the criteria for BRCA testing?</p> <p class="cta-s">Share your family history, diagnosis details, and any existing genetic test results with our team. An Indian genetic oncologist will assess whether testing is indicated and what the results would mean for your treatment — at no charge.</p> <a href="https://gafhealthcare.in/contact" class="btn-green">Get a Free BRCA Assessment →</a> </div>

<h2 id="brca-testing-india">BRCA testing in India — cost, turnaround, and process</h2>

<p>BRCA testing in India is accessible, affordable, and — at the right centres — comprehensive. The test itself is a blood draw. The sample is sent to an accredited genetics laboratory. Results typically come back in ten to fourteen working days.</p>

<p>At GAF Healthcare's partner hospitals, BRCA testing is integrated into the oncology workup — not a separate referral to a different department. Your genetic counsellor, oncologist, and surgical oncologist review the result together and present a coordinated recommendation.</p>

<table class="cost-table"> <thead> <tr> <th>Test</th> <th>USA</th> <th>UK (private)</th> <th class="india-head">India ✦</th> </tr> </thead> <tbody> <tr> <td>BRCA1/2 comprehensive sequencing</td> <td>$300–$2,500</td> <td>£400–£1,500</td> <td class="saving">$80–$200 <span class="saving-pct">~90% less</span></td> </tr> <tr class="highlight"> <td>Targeted variant testing (known family mutation)</td> <td>$150–$400</td> <td>£150–£500</td> <td class="saving">$40–$80 <span class="saving-pct">~80% less</span></td> </tr> <tr> <td>Multi-gene hereditary cancer panel (BRCA + PALB2 + ATM + others)</td> <td>$400–$3,500</td> <td>£500–£2,000</td> <td class="saving">$120–$280 <span class="saving-pct">~92% less</span></td> </tr> <tr class="highlight"> <td>Genetic counselling consultation</td> <td>$200–$500</td> <td>£150–£400</td> <td class="saving">$30–$80 <span class="saving-pct">~85% less</span></td> </tr> <tr> <td>Turnaround time</td> <td>7–14 days</td> <td>10–21 days</td> <td class="saving">10–14 days</td> </tr> </tbody> </table> <p class="sources-line">✦ India figures from GAF Healthcare hospital network laboratory partners, 2025–2026. US figures from Myriad Genetics and Ambry Genetics published pricing. UK figures from private genetics clinic pricing.</p>

<div class="callout-green"> <div class="callout-label">Multi-gene panel testing — why it matters</div> <p>BRCA1 and BRCA2 are the most studied hereditary breast cancer genes — but they are not the only ones. Mutations in PALB2, CHEK2, ATM, RAD51C, and RAD51D also increase breast and ovarian cancer risk. India's accredited genetics laboratories offer multi-gene hereditary cancer panels that test for all of these simultaneously, for approximately $120–$280. This comprehensive approach is recommended by NCCN guidelines for patients meeting hereditary cancer testing criteria — and it is available at Indian costs at all four GAF Healthcare partner hospitals.</p> </div>

<h2 id="positive-result">What a positive result means for your treatment</h2>

<p>A positive BRCA result does not change the treatment for your existing cancer diagnosis in all cases — but it does change several important decisions around surgery, systemic therapy, and risk reduction.</p>

<p>Here is what a positive BRCA result means in practice, for each major decision point.</p>

<div class="option-grid"> <div class="option-card"> <div class="option-head"> <div class="option-num">1</div> <h4>Surgical decision — lumpectomy vs mastectomy</h4> </div> <div class="option-body"> <p>A BRCA mutation does not automatically require mastectomy. Survival outcomes after lumpectomy plus radiation are equivalent to mastectomy for the current cancer — even in BRCA carriers — based on multiple studies including long-term follow-up data.</p> <p>However, BRCA carriers have a higher risk of developing a second primary breast cancer in the same or opposite breast over their lifetime. For many patients, this makes <strong>bilateral risk-reducing mastectomy</strong> — removing both breasts — a rational choice to reduce future risk, even if it is not required for the current cancer.</p> <p>The decision is personal. Some patients choose bilateral mastectomy. Others choose lumpectomy with enhanced surveillance. Both are clinically defensible. India's oncology teams present both options with honest risk data and support the patient's choice.</p> </div> <div class="option-foot"> <p>India bilateral mastectomy + reconstruction cost: $12,000–$22,000 (vs $100,000–$180,000 in the US)</p> </div> </div>

<div class="option-card"> <div class="option-head"> <div class="option-num">2</div> <h4>Systemic therapy — PARP inhibitor eligibility</h4> </div> <div class="option-body"> <p>Patients with germline BRCA1 or BRCA2 mutations who have HER2-negative breast cancer — either hormone receptor-positive or triple-negative — may be eligible for <strong>olaparib</strong> or <strong>talazoparib</strong>, a class of drugs called PARP inhibitors.</p> <p>PARP inhibitors exploit the DNA repair defect caused by the BRCA mutation. Cancer cells that cannot repair DNA damage through the BRCA pathway are particularly vulnerable to PARP inhibition — they accumulate lethal levels of DNA damage and die.</p> <p>The OlympiA trial demonstrated that olaparib significantly improved invasive disease-free survival in high-risk BRCA-mutant HER2-negative breast cancer patients in the adjuvant setting. This makes BRCA testing an important prerequisite for accessing one of the most significant recent advances in breast cancer treatment.</p> <p><strong>Olaparib is available in India</strong> at approximately $1,000–$1,800 per month — compared to $14,000–$18,000 per month in the United States.</p> </div> <div class="option-foot"> <p>PARP inhibitor (olaparib) cost in India: ~$1,000–$1,800/month vs $14,000–$18,000 in USA</p> </div> </div>

<div class="option-card"> <div class="option-head"> <div class="option-num">3</div> <h4>Ovarian risk management</h4> </div> <div class="option-body"> <p>BRCA1 carriers have a 44% lifetime risk of ovarian cancer. BRCA2 carriers have a 17% risk. Both figures are dramatically higher than the general population risk of approximately 1.2%.</p> <p>Risk-reducing salpingo-oophorectomy (RRSO) — surgical removal of the ovaries and fallopian tubes — reduces ovarian cancer risk by approximately 80% in BRCA carriers. It is recommended from age 35–40 for BRCA1 carriers and age 40–45 for BRCA2 carriers, once childbearing is complete.</p> <p>RRSO also reduces breast cancer risk in premenopausal BRCA carriers — because it removes the ovarian source of oestrogen. For BRCA1 carriers who have not yet developed breast cancer, RRSO reduces breast cancer risk by approximately 50%.</p> <p><strong>RRSO cost in India:</strong> $2,500–$5,000 as a laparoscopic procedure — compared to $15,000–$30,000 in the United States. GAF Healthcare coordinates this surgery alongside the breast cancer treatment visit where relevant.</p> </div> <div class="option-foot"> <p>RRSO (laparoscopic) cost in India: $2,500–$5,000 — can be combined with breast cancer treatment visit</p> </div> </div>

<div class="option-card"> <div class="option-head"> <div class="option-num">4</div> <h4>Enhanced surveillance if surgery is declined</h4> </div> <div class="option-body"> <p>Patients who choose not to have risk-reducing surgery are managed with enhanced surveillance — more frequent imaging and closer monitoring than standard breast cancer follow-up protocols.</p> <p>The enhanced surveillance schedule for BRCA carriers typically includes annual breast MRI (more sensitive than mammography for high-risk patients), annual mammography alternating with the MRI, and clinical breast examination every six months.</p> <p><strong>Annual breast MRI cost in India: $120–$250</strong> — compared to $1,500–$3,500 in the United States. For patients on long-term surveillance, this difference compounds significantly across years of follow-up.</p> <p>GAF Healthcare coordinates annual surveillance visits — combining MRI, mammogram, oncology review, and any other indicated assessments in a two to three day visit. The total annual surveillance visit cost in India is typically $400–$700 inclusive.</p> </div> <div class="option-foot"> <p>Annual BRCA surveillance visit cost in India: $400–$700 inclusive (vs $3,000–$6,000 in the US)</p> </div> </div> </div>

<div class="cta-a"> <p class="cta-h">BRCA positive and unsure what it means for your treatment plan?</p> <p class="cta-s">Share your BRCA result, breast cancer diagnosis, and any existing treatment plan. Our India-based oncology and genetics team will outline every option — surgery, drugs, surveillance, and ovarian risk — in a clear written plan. At no charge, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-white">Get My BRCA Treatment Plan →</a> </div>

<h2 id="parp-inhibitors">PARP inhibitors — the drug that targets BRCA mutations</h2>

<p>PARP inhibitors are one of the most significant advances in breast cancer treatment of the past decade. They are the first drugs designed to exploit a specific genetic vulnerability — the DNA repair defect caused by BRCA mutations — rather than attacking cancer cells broadly.</p>

<p>The mechanism is called synthetic lethality. BRCA-mutant cancer cells cannot repair double-strand DNA breaks through the normal pathway. PARP inhibitors block an alternative repair pathway that these cells were using to compensate. Without either repair pathway, the cancer cells accumulate lethal DNA damage and die — while normal cells, which have intact BRCA function, are relatively unaffected.</p>

<div class="stat-strip"> <div class="stat-cell"><div class="stat-label">OlympiA trial: olaparib benefit</div><div class="stat-val">8.8%</div></div> <div class="stat-cell"><div class="stat-label">Absolute iDFS improvement at 3 yr</div><div class="stat-val">Yes</div></div> <div class="stat-cell"><div class="stat-label">Olaparib cost USA (per month)</div><div class="stat-val">$14K+</div></div> <div class="stat-cell"><div class="stat-label">Olaparib cost India (per month)</div><div class="stat-val">~$1,400</div></div> </div>

<p>The OlympiA trial — published in the New England Journal of Medicine — demonstrated that one year of adjuvant olaparib in BRCA-mutant HER2-negative high-risk breast cancer patients significantly improved invasive disease-free survival at three years. The absolute benefit was 8.8 percentage points — a clinically meaningful improvement that has made olaparib a standard adjuvant option in this population.</p>

<p class="impact">"PARP inhibitors are precision medicine in its clearest form. The drug only works if you have the mutation. If you have the mutation, it works very well. BRCA testing is what makes this drug accessible to the patients who need it."</p>

<div class="callout-purple"> <div class="callout-label">Olaparib and talazoparib in India</div> <p>Both olaparib (Lynparza) and talazoparib (Talzenna) are available at <a href="https://gafhealthcare.in/hospitals/apollo-hospitals-new-delhi" style="color:var(--purple);text-decoration:underline;text-decoration-color:var(--purple-border);">Apollo</a>, <a href="https://gafhealthcare.in/hospitals/fortis-memorial-research-institute-gurgaon" style="color:var(--purple);text-decoration:underline;text-decoration-color:var(--purple-border);">Fortis</a>, <a href="https://gafhealthcare.in/hospitals/medanta-the-medicity-gurgaon" style="color:var(--purple);text-decoration:underline;text-decoration-color:var(--purple-border);">Medanta</a>, and <a href="https://gafhealthcare.in/hospitals/tata-memorial-hospital-mumbai" style="color:var(--purple);text-decoration:underline;text-decoration-color:var(--purple-border);">Tata Memorial</a> in India. Olaparib costs approximately $1,000–$1,800 per month in India, compared to $14,000–$18,000 per month in the United States. Over a twelve-month adjuvant course, the saving runs to $145,000–$195,000 on this drug alone. For BRCA-positive patients from Africa or the Gulf who cannot access olaparib at home, India is often the only realistic treatment option.</p> </div>

<a href="https://gafhealthcare.in/treatments/breast-cancer-treatment" class="cta-c"> <div class="cta-arrow">→</div> <div> <div class="rl-label">Full Breast Cancer Treatment Guide — GAF Healthcare</div> <div class="rl-desc">All treatment pathways by stage and subtype — surgery, chemotherapy, targeted therapy, PARP inhibitors, endocrine therapy, costs, and logistics for international patients.</div> </div> </a>

<h2 id="bilateral-mastectomy">Bilateral risk-reducing mastectomy in India</h2>

<p>For BRCA-positive patients who have already been diagnosed with breast cancer in one breast, bilateral mastectomy — removing both the affected breast and the healthy contralateral breast — is a choice many make to reduce future risk.</p>

<p>The decision is personal and irreversible. The evidence on survival benefit from contralateral prophylactic mastectomy for already-diagnosed patients is not definitive — most studies show benefit in BRCA carriers but not in the general breast cancer population. What it does clearly reduce is the risk of a second primary breast cancer in the contralateral breast, which for BRCA1 carriers runs to approximately 40–60% over twenty years.</p>

<p>For patients who have not yet developed breast cancer but carry a BRCA mutation, risk-reducing bilateral mastectomy reduces the risk of ever developing breast cancer by approximately 90%.</p>

<table class="cost-table"> <thead> <tr> <th>Procedure</th> <th>USA</th> <th>UK (private)</th> <th class="india-head">India ✦</th> </tr> </thead> <tbody> <tr> <td>Bilateral mastectomy (without reconstruction)</td> <td>$50,000–$90,000</td> <td>£22,000–£45,000</td> <td class="saving">$6,000–$11,000 <span class="saving-pct">~88% less</span></td> </tr> <tr class="highlight"> <td>Bilateral mastectomy + implant reconstruction</td> <td>$80,000–$130,000</td> <td>£35,000–£60,000</td> <td class="saving">$10,000–$18,000 <span class="saving-pct">~87% less</span></td> </tr> <tr> <td>Bilateral mastectomy + bilateral DIEP reconstruction</td> <td>$120,000–$200,000</td> <td>£55,000–£90,000</td> <td class="saving">$16,000–$28,000 <span class="saving-pct">~87% less</span></td> </tr> <tr class="highlight"> <td>Nipple-sparing bilateral mastectomy + implants</td> <td>$90,000–$150,000</td> <td>£40,000–£70,000</td> <td class="saving">$12,000–$22,000 <span class="saving-pct">~87% less</span></td> </tr> <tr> <td>Risk-reducing salpingo-oophorectomy (RRSO)</td> <td>$15,000–$30,000</td> <td>£8,000–£18,000</td> <td class="saving">$2,500–$5,000 <span class="saving-pct">~85% less</span></td> </tr> </tbody> </table> <p class="sources-line">✦ India figures from GAF Healthcare hospital network, 2025–2026. US and UK figures from FAIR Health and NHS reference costs.</p>

<p><a href="https://gafhealthcare.in/hospitals/medanta-the-medicity-gurgaon" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Medanta — The Medicity</a> is GAF Healthcare's first recommendation for bilateral mastectomy with DIEP reconstruction — individual surgeon volumes above 500 flap procedures produce the most consistent aesthetic and functional outcomes. <a href="https://gafhealthcare.in/hospitals/apollo-hospitals-new-delhi" style="color:var(--green-mid);text-decoration:underline;text-decoration-color:var(--green-border);">Apollo Hospitals</a> is the strongest alternative for implant-based bilateral reconstruction, with a dedicated plastic surgery team and full nipple-sparing capability.</p>

<div class="cta-b"> <p class="cta-h">BRCA positive and considering bilateral mastectomy in India?</p> <p class="cta-s">Share your BRCA result and reconstruction preference. We will recommend the right hospital and surgeon for your specific procedure, provide an itemised cost estimate, and outline the full logistics — at no charge.</p> <a href="https://gafhealthcare.in/contact" class="btn-green">Get My Bilateral Mastectomy Estimate →</a> </div>

<h2 id="family-implications">What a positive result means for your family</h2>

<p>A BRCA result is not just your result. Each first-degree relative — parents, siblings, children — has a 50% chance of carrying the same mutation. A positive result in your family creates a clinical obligation to inform relatives so they can make their own testing decisions.</p>

<p>This is one of the reasons genetic counselling is integrated into the BRCA testing process at GAF Healthcare's partner hospitals. The counsellor helps you understand the result, think through the family implications, and decide how and whether to communicate with relatives.</p>

<div class="callout-red"> <div class="callout-label">Testing family members in India — practical considerations</div> <p>If you test positive in India, targeted variant testing for your specific mutation is available for family members at approximately $40–$80 per person. Some families choose to bring one or two relatives on the same trip — testing siblings or adult daughters while the primary patient is undergoing treatment, without requiring a separate visit. GAF Healthcare can coordinate simultaneous testing for multiple family members during the same India visit where this is practical and the family chooses to proceed.</p> </div>

<p>For unaffected BRCA carriers — family members who test positive but have not yet developed cancer — India offers the full spectrum of risk management options: enhanced surveillance, chemoprevention (tamoxifen or raloxifene), risk-reducing mastectomy, and RRSO. All at Indian costs, coordinated through GAF Healthcare.</p>

<p class="impact">"When my mother tested positive in India, we had my sister tested the same week. She was positive too. She had her bilateral mastectomy six months later, before she ever developed cancer. That is what the test made possible."</p>

<div class="cta-a"> <p class="cta-h">BRCA positive — or think you might be. India is where to find out and what to do next.</p> <p class="cta-s">Share your family history, diagnosis, and any existing genetic test results. Our India-based genetics and oncology team will assess your situation, recommend testing if indicated, and outline every option available — at no charge, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-white">Start My Free BRCA Consultation →</a> </div>

<a href="https://gafhealthcare.in/treatments/breast-cancer-treatment" class="cta-c"> <div class="cta-arrow">→</div> <div> <div class="rl-label">Full Breast Cancer Treatment Guide — GAF Healthcare</div> <div class="rl-desc">Surgery, chemotherapy, PARP inhibitors, endocrine therapy, genetic testing, and costs — everything international patients need to plan breast cancer treatment in India.</div> </div> </a>

</div> </div> </body> </html>